Adenocarcinoma of the Rectum Clinical Trial
Official title:
Phase I Repeat-Dose Study of Resveratrol in Colorectal Cancer Patients: Tolerability, Target Tissue Levels and Pharmacodynamics
This phase I trial is studying the side effects and best dose of resveratrol in treating patients with colorectal cancer that can be removed by surgery. Resveratrol may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
OBJECTIVES:
I. Determine the relationship between oral dose of resveratrol and the colon mucosal levels
of resveratrol and its metabolites in patients with resectable colorectal cancer.
II. Determine the relationship between colon mucosal levels of resveratrol and its
metabolites and plasma concentrations of resveratrol and its metabolites in these patients.
III. Determine cyclooxygenase-2 (COX-2) expression in colorectal cancer tissue before and
after treatment in these patients.
IV. Determine M_1G concentration in colonic cancer tissue and in circulating white blood
cells (WBC) before and after treatment.
V. Correlate M_1G concentration in colorectal cancer tissue with M_1G concentration in
circulating WBC.
VI. Assess the Ki67 labeling index in normal and malignant tissues in at least 10 fields per
section.
VII. Correlate COX-2 expression in colorectal cancer tissue with COX-2 expression in
circulating WBCs.
VIII. Assess the toxicity profile of this drug.
OUTLINE: This is a two-stage nonrandomized, open-label study. Patients are assigned to 1 of
2 dose levels in stage 2.
STAGE I: Patients undergo an colorectal endoscopy. Patients whose biopsies confirm
colorectal adenocarcinoma histology and require surgical resection continue on study stage
2.
STAGE II: Patients receive oral resveratrol on days 1-8. Patients undergo colorectomy on day
9. A tumor biopsy is performed during endoscopy and colorectomy for research purposes.
Two biomarkers of the potential activity of resveratrol are measured in nonmalignant and
malignant colorectal tissue biopsy samples: levels of M_1G adducts by immunoslot blot
analysis and levels of cyclooxygenase-2 protein/Ki67 by immunohistochemistry. Blood samples
are collected at baseline and during colorectomy for analysis of resveratrol and its
metabolites and other pharmacokinetic studies.
;
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00025337 -
Combination Chemotherapy With or Without Bevacizumab Compared With Bevacizumab Alone in Treating Patients With Advanced or Metastatic Colorectal Cancer That Has Been Previously Treated
|
Phase 3 | |
| Completed |
NCT03871959 -
Pembrolizumab In Combination With Debio 1143 In Pancreatic and Colorectal Advanced/Metastatic Adenocarcinoma
|
Phase 1 | |
| Recruiting |
NCT05080673 -
Five or Ten Year Colonoscopy for 1-2 Non-Advanced Adenomatous Polyps
|
N/A | |
| Completed |
NCT01037790 -
Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer
|
Phase 2 | |
| Completed |
NCT00707889 -
Phase 2 Study of ABT-869 in Combination With mFOLFOX6 Versus Bevacizumab in Combination With mFOLFOX6 to Treat Advanced Colorectal Cancer
|
Phase 2 | |
| Completed |
NCT00551421 -
Pertuzumab and Cetuximab in Treating Patients With Previously Treated Locally Advanced or Metastatic Colorectal Cancer
|
Phase 1/Phase 2 | |
| Terminated |
NCT00052585 -
Gefitinib and Combination Chemotherapy in Treating Patients With Advanced or Recurrent Colorectal Cancer
|
Phase 2 | |
| Completed |
NCT00023933 -
Radiolabeled Monoclonal Antibody Therapy in Treating Patients With Recurrent or Persistent Metastatic Colorectal Cancer
|
Phase 1 | |
| Recruiting |
NCT03303547 -
Concordance of Imaging and Pathology Diagnosis of Extranodal Tumour Deposits
|
N/A | |
| Active, not recruiting |
NCT01037049 -
Optimum Timing for Surgery After Pre-operative Radiotherapy 6 vs 12 Weeks
|
Phase 2 | |
| Terminated |
NCT00397878 -
AZD0530 (NSC 735464) in Treating Patients With Previously Treated Metastatic Colon Cancer or Rectal Cancer
|
Phase 2 | |
| Completed |
NCT00100841 -
Phase II Trial of FOLFOX6, Bevacizumab and Cetuximab in Patients With Colorectal Cancer
|
Phase 2 | |
| Completed |
NCT00028496 -
Vaccine Therapy With or Without Sargramostim in Treating Patients With Advanced or Metastatic Cancer
|
Phase 1 | |
| Recruiting |
NCT04005118 -
Human Intestinal Microbiome and Surgical Outcomes in Patients Undergoing Colorectal Cancer Surgery
|
||
| Completed |
NCT02641691 -
Non-Operative Radiation Management of Adenocarcinoma of the Lower Rectum
|
Phase 2 | |
| Completed |
NCT00307736 -
Bevacizumab, Erlotinib and 5-Fluorouracil With External Beam Radiation Therapy in Locally Advanced Rectal Cancer
|
Phase 1/Phase 2 | |
| Completed |
NCT00003799 -
Chemotherapy, Radiation Therapy, and Surgery in Treating Patients With Locally Advanced Rectal Cancer
|
Phase 1 | |
| Terminated |
NCT00303628 -
Postoperative Chemotherapy With or Without Bevacizumab for Patients With Stage II or III Rectal Cancer
|
Phase 3 | |
| Terminated |
NCT02425683 -
Study of Colorectal Cancer Patients (Stage IIIC) With Either Regorafenib or Standard of Care (No Treatment) After Adjuvant FOLFOX
|
Phase 2 | |
| Recruiting |
NCT05669430 -
A Study of GV20-0251 in Patients With Solid Tumor Malignancies
|
Phase 1 |